Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 606-610

  Garrigós, Carmen ^a   Murillo, O ^a   Lora Tamayo, J ^a   Verdaguer, R ^a   Tubau, F ^a   Cabellos, C ^a   Cabo, J ^a   Ariza, J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; IMIPENEM; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL INFECTION; FOREIGN BODY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FOREIGN-BODY REACTION; FOSFOMYCIN; IMIPENEM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS;

EID: 84872032456     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01570-12     Document Type: Article

References (28)

1. Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2010. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5251-5256. doi:10.1128/AAC.00226-10.
2. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
3. Chen LY, Huang CH, Kuo SC, Hsiao CY, Lin ML, Wang FD, Fung CP. 2011. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect. Dis. 11:152.
4. Debbia E, Pesce A, Schito GC. 1988. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob. Agents Chemother. 32:279-281.
5. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. 2009. Fosfomycin for the treatment of infections caused by Grampositive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin. Invest. Drugs. 18:921-944.
6. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, Giddey M, Armero Y, Pericas JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A, the Hospital Clinic Experimental Endocarditis Study Group. 2012. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 56:4511-4515.
7. Miró JM, Marco F, GarcíA C, GavaldÁ J, del Río A, Dern E, Almela M, Soy D, Torra M, Gatell JM, Jimenez de Anta MT. 1999. Efficacy of the fosfomicin (Fos) plus imipenem (I) combination in the treatment of experimental endocarditis (EE) caused by methicillin-resistant Staphylococcus aureus (MRSA), abstr 1015. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC), San Diego, CA.
8. Pachon-Ibanez ME, Ribes S, Dominguez MA, Fernandez R, Tubau F, Ariza J, Gudiol F, Cabellos C. 2011. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 30:89-95.
9. Portier H, Kazmierczak A, Lucht F, Tremeaux JC, Chavanet P, Duez JM. 1985. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 13(Suppl 1):S123-S128.
10. Portier H, Tremeaux JC, Chavanet P, Gouyon JB, Duez JM, Kazmierczak A. 1984. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J. Antimicrob. Chemother. 14(Suppl B):277-284.
11. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard, 8th ed, M7-A8. CLSI, Wayne, PA.
12. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2012. Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:3806-3811.
13. Zimmerli W, Frei R, Widmer AF, Rajacic Z. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.
14. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. M26-A. NCCLS, Wayne, PA.
15. Mascio CT, Alder JD, Silverman JA. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:4255-4260.
16. Murillo O, Domenech A, García A, Tubau F, Cabellos C, Gudiol F, Ariza J. 2006. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50:4011-4017.
17. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10, quiz 11-12.
18. Trampuz A, Wenk M, Rajacic Z, Zimmerli W. 2000. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob. Agents Chemother. 44:1352-1355.
19. Schaad HJ, Chuard C, Vaudaux P, Rohner P, Waldvogel FA, Lew DP. 1994. Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus. J. Antimicrob. Chemother. 33:1191-1200.
20. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34:506-515.
21. Tang HJ, Chen CC, Cheng KC, Toh HS, Su BA, Chiang SR, Ko WC, Chuang YC. 2012. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J. Antimicrob. Chemother. 67:944-950.
22. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Georgopoulos A, Burgmann H. 2011. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:931-933.
23. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H, Georgopoulos A, Burgmann H. 2011. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob. Agents Chemother. 55:4999-5003.
24. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
25. Quentin C, Noury P, Laurent C, Saivin S, Bebear C. 1987. In vitro action of fosfomycin combined with rifampicin, pefloxacin and imipenem on staphylococci (checkerboard method in a liquid medium). Pathol. Biol. (Paris) 35:153-157. (In French.)
26. Quentin C, Saivin S, Lafferriere C, Noury P, Bebear C. 1987. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method. Drugs Exp. Clin. Res. 13:219-224.
27. Mihailescu R, Furustrand Tafin U, Bétrisey B, Rio L, Maiolo E, Borens O, Trampuz A. 2012. High efficacy of fosfomycin-rifampin combination against methicillin-resistant Staphylococcus aureus in an experimental model of foreign-body infection, abstr P-2062. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. (ECCMID), London, United Kingdom.
28. Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2011. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus. J. Infect. 63:229-235.